Double-intensive therapy in high-risk multiple myeloma

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• High-dose melphalan (HDM) followed by autologous hematopoietic stem cell transplantation (ASCT) is a standard treatment for multiple myeloma (MM).
• Assessing the efficacy and safety of a first HDM course and a potential second course with ASCT in high-risk MM patients is crucial.

Purpose of the Study:

• To evaluate the response rates, toxicity, and survival outcomes of high-dose melphalan (HDM) in patients with high-risk multiple myeloma (MM).
• To assess the feasibility and impact of a second HDM course with stem cell support in responding patients.

Main Methods:

• A total of 97 high-risk multiple myeloma patients received a first course of HDM.
• Responding patients were offered a second course of high-dose therapy with stem cell support (autologous or allogeneic).
• Outcomes including response rates, duration of neutropenia and thrombocytopenia, toxic deaths, and survival were analyzed.

Main Results:

• The first HDM course achieved an overall response rate of 71% and a complete remission rate of 25%.
• Severe myelosuppression led to 8 toxic deaths, with only 38 of 69 responders proceeding to a second course.
• Median survival was 24 months, with age and response to HDM being significant prognostic factors.

Conclusions:

• HDM is effective in inducing responses in high-risk MM but is associated with significant toxicity.
• The feasibility of a second HDM course is limited by severe myelosuppression and toxic deaths.
• While HDM can prolong survival, it may not eradicate the malignant clone, suggesting the need for novel therapeutic strategies.